This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will J&J (JNJ) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.
Key Biosimilar Approvals in 2017: Progress Report
by Zacks Equity Research
The biosimilar space was much in focus as the FDA approved a few biosimilars for key blockbuster drugs. We expect investor focus on the same in 2018 as well.
3 Large-Cap Pharma Stocks to Watch Out for This New Year
by Zacks Equity Research
We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.
AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.
Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) immuno-oncology drug Yervoy gets positive opinion from the CHMP of the European Medicines Agency for the treatment of pediatric patients of 12 years and older with unresectable or metastatic melanoma.
Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA
by Zacks Equity Research
Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Roche/AbbVie Report Positive Phase III Results on Venclexta
by Zacks Equity Research
Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.
Novartis Announces Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.
AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan
by Zacks Equity Research
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
by Arpita Dutt
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study
by Zacks Equity Research
AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance.
Lilly's (LLY) Taltz Gets Approval for Label Expansion in US
by Zacks Equity Research
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained 32.1% so far in the second half of the year supported by a series of positive news in the past few months.
The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt
J&J & Glaxo's Juluca Approval Puts Spotlight on HIV Space (Revised)
by Zacks Equity Research
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
Will New Drug Approvals Boost Novartis (NVS) Portfolio?
by Zacks Equity Research
Novartis (NVS) is facing stiff generic competition for key drugs. Nevertheless, we expect approval of new drugs to boost its portfolio.
Galapagos' CF Candidate Shows Potential in Phase II Study
by Zacks Equity Research
Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.
Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US
by Zacks Equity Research
Amgen launched its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval
by Zacks Equity Research
Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
by Zacks Equity Research
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Novartis (NVS) Arm's Biosimilars Study Results Encourage
by Zacks Equity Research
Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.